tiprankstipranks
Trending News
More News >
Basilea Pharmaceutica (CH:BSLN)
:BSLN

Basilea Pharmaceutica (BSLN) Stock Statistics & Valuation Metrics

Compare
1 Followers

Total Valuation

Basilea Pharmaceutica has a market cap or net worth of CHF613.65M. The enterprise value is CHF609.47M.
Market CapCHF613.65M
Enterprise ValueCHF609.47M

Share Statistics

Basilea Pharmaceutica has 13,313,530 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding13,313,530
Owned by Insiders
Owned by Institutions0.11%

Financial Efficiency

Basilea Pharmaceutica’s return on equity (ROE) is 0.96 and return on invested capital (ROIC) is 36.76%.
Return on Equity (ROE)0.96
Return on Assets (ROA)0.30
Return on Invested Capital (ROIC)36.76%
Return on Capital Employed (ROCE)0.29
Revenue Per Employee1.27M
Profits Per Employee473.13K
Employee Count164
Asset Turnover0.81
Inventory Turnover1.22

Valuation Ratios

The current PE Ratio of Basilea Pharmaceutica is 6.44. Basilea Pharmaceutica’s PEG ratio is <0.01.
PE Ratio6.44
PS Ratio0.00
PB Ratio8.41
Price to Fair Value6.17
Price to FCF8.51
Price to Operating Cash Flow9.16
PEG Ratio<0.01

Income Statement

In the last 12 months, Basilea Pharmaceutica had revenue of 208.54M and earned 77.59M in profits. Earnings per share was 6.42.
Revenue208.54M
Gross Profit169.86M
Operating Income61.18M
Pretax Income60.26M
Net Income77.59M
EBITDA63.13M
Earnings Per Share (EPS)6.42

Cash Flow

In the last 12 months, operating cash flow was 74.36M and capital expenditures -1.71M, giving a free cash flow of 72.65M billion.
Operating Cash Flow74.36M
Free Cash Flow72.65M
Free Cash Flow per Share5.46

Dividends & Yields

Basilea Pharmaceutica pays an annual dividend of CHF5, resulting in a dividend yield of ―
Dividend Per ShareCHF5
Dividend Yield
Payout RatioN/A
Free Cash Flow Yield
Earnings Yield

Stock Price Statistics

Beta1.01
52-Week Price Change20.43%
50-Day Moving Average43.89
200-Day Moving Average43.49
Relative Strength Index (RSI)80.65
Average Volume (3m)35.75K

Important Dates

Basilea Pharmaceutica upcoming earnings date is Aug 19, 2025, TBA Not Confirmed.
Last Earnings DateFeb 18, 2025
Next Earnings DateAug 19, 2025
Ex-Dividend DateApr 11, 2013

Financial Position

Basilea Pharmaceutica as a current ratio of 4.85, with Debt / Equity ratio of 137.87%
Current Ratio4.85
Quick Ratio4.16
Debt to Market Cap0.19
Net Debt to EBITDA-0.14
Interest Coverage Ratio14.08

Taxes

In the past 12 months, Basilea Pharmaceutica has paid -17.33M in taxes.
Income Tax-17.33M
Effective Tax Rate-0.29

Enterprise Valuation

Basilea Pharmaceutica EV to EBITDA ratio is 7.78, with an EV/FCF ratio of 6.76.
EV to Sales2.35
EV to EBITDA7.78
EV to Free Cash Flow6.76
EV to Operating Cash Flow6.60

Balance Sheet

Basilea Pharmaceutica has CHF120.71M in cash and marketable securities with CHF111.67M in debt, giving a net cash position of -CHF9.04M billion.
Cash & Marketable SecuritiesCHF120.71M
Total DebtCHF111.67M
Net Cash-CHF9.04M
Net Cash Per Share-CHF0.68
Tangible Book Value Per ShareCHF6.67

Margins

Gross margin is 60.57%, with operating margin of 29.34%, and net profit margin of 37.21%.
Gross Margin60.57%
Operating Margin29.34%
Pretax Margin28.90%
Net Profit Margin37.21%
EBITDA Margin30.27%
EBIT Margin29.59%

Analyst Forecast

The average price target for Basilea Pharmaceutica is CHF83.50, which is 11.43% higher than the current price. The consensus rating is Moderate Buy
Price TargetCHF83.50
Price Target Upside65.67% Upside
Analyst ConsensusModerate Buy
Analyst Count2
Revenue Growth Forecast32.30%
EPS Growth Forecast631.04%

Scores

Smart ScoreN/A
AI Score75
What am I Missing?
Make informed decisions based on Top Analysts' activity
Know what industry insiders are buying
Get actionable alerts from top Wall Street Analysts
Find out before anyone else which stock is going to shoot up
Get powerful stock screeners & detailed portfolio analysis